Covid-19 (Temas de Saúde Pública)
Vacinas contra COVID-19 e variantes do SARS-CoV-2.
27 Set, 2021 | 12:43hCOVID-19 vaccines: Keeping pace with SARS-CoV-2 variants – Cell
Comentário no Twitter
COVID-19 #vaccines: Keeping pace with SARS-CoV-2 #variants. Timely commentary on understanding #immune correlates and laboratory findings in the context vaccine efficacy from @mugecevik @NathanGrubaugh @VirusesImmunity @p_openshaw https://t.co/o4GoChq5RM #COVID19 #SARSCoV2 pic.twitter.com/UuWqWa711K
— Sri Baqri (Narasimhan) (@Sri_Baqri) September 17, 2021
Estudo randomizado de fase 1/2 | Segurança e imunogenicidade de vacina inativada contra COVID-19 (BBIBP-CorV) em crianças e adolescentes de 3 a 17 anos de idade.
27 Set, 2021 | 12:11hConteúdo relacionado: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
“Não é um jogo de soma zero”: compartilhar vacinas é do interesse de todos os países.
27 Set, 2021 | 12:06h‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests – YaleNews
Artigo original: National interest may require distributing COVID-19 vaccines to other countries – Scientific Reports
Comentário no Twitter
"when US has reached the threshold for domestic herd immunity, it would be optimal to donate doses to other countries, as this would allow for a sharp reduction in the inflow of infected individuals from abroad"
– Modeling by @SaadOmer3, @amynmalik & co https://t.co/NFfp39tde6— Ahmed Mushfiq Mobarak (@mushfiq_econ) September 16, 2021
OMS lança novo compêndio de tecnologias inovadoras de saúde para COVID-19 e outras doenças prioritárias.
27 Set, 2021 | 12:02h[Comunicado de imprensa – ainda não publicado] J&J afirma que dose de reforço depois de 2 meses propiciou 75% de proteção contra COVID-19 moderada a grave globalmente, sendo 94% desses casos nos EUA.
27 Set, 2021 | 11:39hComunicado de imprensa: Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Comentários:
Johnson & Johnson says additional dose boosts Covid vaccine efficacy – STAT
J&J booster 94% effective against severe COVID, company says – CIDRAP
Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds – CNN
Comentários no Twitter
(fio – clique para saber mais)
📍BREAKING—At last—new data on 2-doses of Johnson & Johnson's #vaccine (doses 56 days apart) is 94% effective against symptomatic #COVID19, thus comparable to Moderna/Pfizer. And 100% effective against severe COVID. Booster for 1 dose works well too. 🧵https://t.co/3nPkodOjuG pic.twitter.com/DizjWt9NYX
— Eric Feigl-Ding (@DrEricDing) September 21, 2021
(fio – clique para saber mais)
First press released results out for the double-dose J&J vax trial, ENSEMBLE 2. With 2 months between doses, efficacy against moderate to severe/critical increased – didn't provide overall efficacy data though. Adverse reactions similar to 1st dose …1/n https://t.co/BmBVtLvEaW
— Hilda Bastian, PhD (@hildabast) September 21, 2021
Perspectiva | Desculpe, mas uma infecção por coronavírus pode não ser o suficiente para proteger você – “Qualquer um que prefira ter COVID-19 do que se vacinar está fazendo uma aposta dupla: que a imunidade se mantenha, e os sintomas, não.”
27 Set, 2021 | 11:35hSorry, a Coronavirus Infection Might Not Be Enough to Protect You – The Atlantic
[Preprint] Vírus parecidos com SARS podem passar de animais para pessoas centenas de milhares de vezes ao ano.
27 Set, 2021 | 11:34hSARS-like viruses may jump from animals to people hundreds of thousands of times a year – Science
Estudo original: A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia – medRxiv
Conteúdos relacionados:
Did the coronavirus jump from animals to people twice? – Nature
The Origins of SARS-CoV-2: A Critical Review.
Fauci says natural origins theory of coronavirus is still the most likely.
A batalha para fabricar vacinas contra COVID em países de baixa renda.
27 Set, 2021 | 11:33hThe fight to manufacture COVID vaccines in lower-income countries – Nature
[Comunicado de imprensa – ainda não publicado] Pfizer anuncia que sua vacina contra COVID-19 produz forte resposta imune em crianças de 5 a 11 anos.
27 Set, 2021 | 11:00hComentários:
Pfizer says COVID-19 vaccine safe, effective in younger children – CIDRAP
Comentários no Twitter
I'm so glad to see that Pfizer has data to submit for their vaccine for 5-11 year olds. But any strong assertions about safety, such as for low incidence side-effects like myocarditis, cannot made from a trial of ~1500 children.
— Eric Topol (@EricTopol) September 20, 2021
(fio – clique para saber mais)
BREAKING NEWS: Pfizer releases results of 5-11 year old trial for its vaccine. 2-dose 10 microgram regimen (Pfizer uses 30 mcg for 12 and up) administered 21 days apart (sigh, we now know we need longer duration between doses for better effectiveness)https://t.co/43MHnlZgqg
— Monica Gandhi MD, MPH (@MonicaGandhi9) September 20, 2021
(fio – clique para saber mais)
BNT-Pfizer vax trial readout (press release) for kids 5-11: it's 2 doses of 10 µg dose – a third of the size of that for 12+. They conclude it had similar results to full dose vax for the 16-25 year age group: minimal data in press release…1/3https://t.co/MgYCmWYhO2
— Hilda Bastian, PhD (@hildabast) September 20, 2021
Desatrelando a vacinação da política: um chamado para a ação.
27 Set, 2021 | 10:57hUncoupling vaccination from politics: a call to action – The Lancet